Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Argenx Se ( (ARGX) ) is now available.
Argenx SE, the Euronext and Nasdaq-listed immunology specialist, has called its Annual General Meeting of shareholders for May 6, 2026, at Schiphol near Amsterdam. Shareholders and other eligible participants can attend in person or by proxy, with detailed registration and e-voting information available via the company’s website and its banking partner’s online portal.
Alongside standard AGM items such as approval of the 2025 accounts, an advisory vote on the 2025 remuneration report and director discharge, argenx will seek shareholder authorization for the board to issue shares and limit or exclude pre-emptive rights, and will propose several board changes. The agenda includes the appointment of Karen Massey as executive director, the appointment of CEO Tim Van Hauwermeiren as non-executive director, and the re-appointment of Ana Céspedes, Camilla Sylvest and Pamela Klein, while long-serving non-executive director Jim Daly will retire and the board reviews options for his succession as chair of the Commercialization Committee, signaling an orderly refresh of governance as argenx scales its commercial operations.
The most recent analyst rating on (ARGX) stock is a Buy with a $1000.00 price target. To see the full list of analyst forecasts on Argenx Se stock, see the ARGX Stock Forecast page.
Spark’s Take on ARGX Stock
According to Spark, TipRanks’ AI Analyst, ARGX is a Outperform.
Score is driven primarily by strong financial performance (rapid 2025 growth, high margins, and a very conservative balance sheet) and a constructive earnings-call outlook with meaningful label-expansion catalysts. Offsetting factors are weak near-term technical momentum and a premium valuation with no dividend support, plus execution risks from low reported gross margin and rising OpEx.
To see Spark’s full report on ARGX stock, click here.
More about Argenx Se
Argenx SE is a global immunology company focused on treating severe autoimmune diseases through novel antibody-based medicines. It developed and commercializes the first approved neonatal Fc receptor blocker and is advancing a pipeline of experimental therapies, leveraging partnerships with academic researchers to expand its immunology portfolio across multiple serious indications.
Average Trading Volume: 359,092
Technical Sentiment Signal: Buy
Current Market Cap: $42.45B
For an in-depth examination of ARGX stock, go to TipRanks’ Overview page.